These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 12466739)

  • 21. Re: Estrogen plus progestin therapy and breast cancer in recently postmenopausal women.
    Langer RD
    Am J Epidemiol; 2009 Mar; 169(6):784-5; author reply 785-6. PubMed ID: 19208722
    [No Abstract]   [Full Text] [Related]  

  • 22. Menopausal hormone therapy: currently no evidence for cardiac protection.
    Wenger NK
    Pediatr Blood Cancer; 2005 Jun; 44(7):625-9. PubMed ID: 15747336
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hormone therapy and cardiovascular disease in the early postmenopause: the WHI data revisited.
    Pines A; Sturdee DW; Birkhäuser MH;
    Climacteric; 2007 Jun; 10(3):195-6. PubMed ID: 17487646
    [No Abstract]   [Full Text] [Related]  

  • 24. [Health symptom-free women do not need preventive hormone replacement therapy. The risks outweigh the benefits; a large trial prematurely interrupted in the USA].
    von Schoultz B
    Lakartidningen; 2002 Aug; 99(34):3276-8. PubMed ID: 12362844
    [No Abstract]   [Full Text] [Related]  

  • 25. The impact of the Women's Health Initiative on hormone replacement therapy in a Medicaid program.
    Hillman JJ; Zuckerman IH; Lee E
    J Womens Health (Larchmt); 2004 Nov; 13(9):986-92. PubMed ID: 15665655
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined analysis of Women's Health Initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease.
    Prentice RL; Langer RD; Stefanick ML; Howard BV; Pettinger M; Anderson GL; Barad D; Curb JD; Kotchen J; Kuller L; Limacher M; Wactawski-Wende J;
    Am J Epidemiol; 2006 Apr; 163(7):589-99. PubMed ID: 16484450
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Abbreviated hormone replacement therapy trial answers some questions, raises new ones. The Women's Health Initiative is no longer testing the most widely prescribed estrogen and progestin combination--but the study's job is far from over.
    Harv Womens Health Watch; 2002 Oct; 10(2):2-4. PubMed ID: 12393317
    [No Abstract]   [Full Text] [Related]  

  • 28. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin.
    Anderson GL; Chlebowski RT; Rossouw JE; Rodabough RJ; McTiernan A; Margolis KL; Aggerwal A; David Curb J; Hendrix SL; Allan Hubbell F; Khandekar J; Lane DS; Lasser N; Lopez AM; Potter J; Ritenbaugh C
    Maturitas; 2006 Sep; 55(2):103-15. PubMed ID: 16815651
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Postmenopausal hormone therapy: cardiovascular risks.
    Prescrire Int; 2003 Apr; 12(64):65-9. PubMed ID: 12674130
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Good science or good marketing?
    Head K
    Altern Med Rev; 2002 Aug; 7(4):274-5. PubMed ID: 12197780
    [No Abstract]   [Full Text] [Related]  

  • 31. [The combination on conjugated estrogens and medroxyprogesterone in the post-menopause patient and risk of breast cancer: analysis of an uncertain statistic].
    Palma-Aguirre JA; del-Razo OE
    Gac Med Mex; 2002; 138(6):591-2. PubMed ID: 12532627
    [No Abstract]   [Full Text] [Related]  

  • 32. Is the estrogen controversy over? Deconstructing the Women's Health Initiative study: a critical evaluation of the evidence.
    Harman SM; Naftolin F; Brinton EA; Judelson DR
    Ann N Y Acad Sci; 2005 Jun; 1052():43-56. PubMed ID: 16024750
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reconsidering HRT.
    Cowley G; Springen K
    Newsweek; 2002 Apr; 139(17):71. PubMed ID: 11989385
    [No Abstract]   [Full Text] [Related]  

  • 34. A doctor talks about: why researchers stopped the Women's Health Initiative study of estrogen and progestin and what this means for you.
    Robb-Nicholson C
    Harv Womens Health Watch; 2002 Sep; 10(1):8. PubMed ID: 12356550
    [No Abstract]   [Full Text] [Related]  

  • 35. Health risks after cessation of postmenopausal hormone therapy.
    Pines A; Sturdee D; Birkhäuser M;
    Climacteric; 2008 Jun; 11(3):179-80. PubMed ID: 18568782
    [No Abstract]   [Full Text] [Related]  

  • 36. Do risks of hormone therapy persist after discontinuation?
    J Fam Pract; 2008 Jun; 57(6):366, 369. PubMed ID: 18677802
    [No Abstract]   [Full Text] [Related]  

  • 37. Risks of estrogen plus progestin therapy: a sensitivity analysis of findings in the Women's Health Initiative randomized controlled trial.
    Shapiro S
    Climacteric; 2003 Dec; 6(4):302-10; discussion 310-3. PubMed ID: 15006251
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Women's Health Initiative: not over yet. The largest study of women's health has raised at least as many questions as it has answered. Stay tuned.
    Harv Womens Health Watch; 2006 May; 13(9):1-4. PubMed ID: 16696133
    [No Abstract]   [Full Text] [Related]  

  • 39. Attitudes of Korean clinicians to postmenopausal hormone therapy after the Women's Health Initiative study.
    Kang BM; Kim MR; Park HM; Yoon BK; Lee BS; Chung HW; Cho SH; Choi H; Kim JG
    Menopause; 2006; 13(1):125-9. PubMed ID: 16607108
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of WHI conclusions and ACOG guidelines on clinical practice.
    Gass M
    Int J Fertil Womens Med; 2003; 48(3):106-10; discussion 137-8. PubMed ID: 12839140
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.